NCT01660776View on ClinicalTrials.gov

BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology

CompletedOBSERVATIONAL
Enrollment

105

Participants

Timeline

Start Date

June 7, 2012

Primary Completion Date

October 2, 2017

Study Completion Date

October 2, 2019

Conditions
Diffuse Large B-cell LymphomaHodgkin LymphomaMetastatic BreastcancerNon-small Cell Lung Cancer
Trial Locations (4)

13000

Institut Paoli Calmette, Marseille

34000

Montpellier University Hospital, Montpellier

35000

Rennes EFS, Rennes

Rennes University Hospital, Rennes

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

collaborator

National Research Agency, France

OTHER

lead

Rennes University Hospital

OTHER

NCT01660776 - BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology | Biotech Hunter | Biotech Hunter